Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 3.73
ALNY's Cash-to-Debt is ranked lower than
63% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. ALNY: 3.73 )
Ranked among companies with meaningful Cash-to-Debt only.
ALNY' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.29  Med: No Debt Max: No Debt
Current: 3.73
Equity-to-Asset 0.73
ALNY's Equity-to-Asset is ranked higher than
59% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ALNY: 0.73 )
Ranked among companies with meaningful Equity-to-Asset only.
ALNY' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.99  Med: 0.64 Max: 0.92
Current: 0.73
-0.99
0.92
Interest Coverage N/A
ALNY's Interest Coverage is ranked lower than
53% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALNY: N/A )
Ranked among companies with meaningful Interest Coverage only.
ALNY' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: N/A
N/A
No Debt
Piotroski F-Score: 2
Altman Z-Score: 8.43
Beneish M-Score: -2.17
WACC vs ROIC
22.95%
-111.75%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -716.42
ALNY's Operating Margin % is ranked lower than
76% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. ALNY: -716.42 )
Ranked among companies with meaningful Operating Margin % only.
ALNY' s Operating Margin % Range Over the Past 10 Years
Min: -900.33  Med: -188.54 Max: -28.95
Current: -716.42
-900.33
-28.95
Net Margin % -705.11
ALNY's Net Margin % is ranked lower than
77% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. ALNY: -705.11 )
Ranked among companies with meaningful Net Margin % only.
ALNY' s Net Margin % Range Over the Past 10 Years
Min: -869.63  Med: -163.4 Max: -27.3
Current: -705.11
-869.63
-27.3
ROE % -41.00
ALNY's ROE % is ranked lower than
51% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. ALNY: -41.00 )
Ranked among companies with meaningful ROE % only.
ALNY' s ROE % Range Over the Past 10 Years
Min: -84.12  Med: -39.64 Max: -13.08
Current: -41
-84.12
-13.08
ROA % -32.33
ALNY's ROA % is ranked lower than
51% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. ALNY: -32.33 )
Ranked among companies with meaningful ROA % only.
ALNY' s ROA % Range Over the Past 10 Years
Min: -48.05  Med: -23.41 Max: -5.01
Current: -32.33
-48.05
-5.01
ROC (Joel Greenblatt) % -512.30
ALNY's ROC (Joel Greenblatt) % is ranked lower than
57% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. ALNY: -512.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ALNY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2120.98  Med: -554.62 Max: -149.42
Current: -512.3
-2120.98
-149.42
3-Year Revenue Growth Rate -10.40
ALNY's 3-Year Revenue Growth Rate is ranked lower than
68% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. ALNY: -10.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ALNY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -8.15 Max: 108
Current: -10.4
0
108
3-Year EBITDA Growth Rate 52.70
ALNY's 3-Year EBITDA Growth Rate is ranked higher than
90% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. ALNY: 52.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ALNY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -64.8  Med: 3.5 Max: 65.3
Current: 52.7
-64.8
65.3
3-Year EPS without NRI Growth Rate 48.90
ALNY's 3-Year EPS without NRI Growth Rate is ranked higher than
90% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. ALNY: 48.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ALNY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -66.7  Med: 6.6 Max: 52.8
Current: 48.9
-66.7
52.8
GuruFocus has detected 2 Warning Signs with Alnylam Pharmaceuticals Inc $ALNY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ALNY's 30-Y Financials

Financials (Next Earnings Date: 2017-08-05 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

ALNY Guru Trades in Q2 2016

Dodge & Cox 2,516,669 sh (New)
John Paulson 19,300 sh (+56.91%)
John Griffin 1,320,000 sh (+22.79%)
Vanguard Health Care Fund 8,512,270 sh (unchged)
Jim Simons 18,673 sh (-91.27%)
» More
Q3 2016

ALNY Guru Trades in Q3 2016

Dodge & Cox 5,276,068 sh (+109.64%)
Vanguard Health Care Fund 8,512,270 sh (unchged)
John Griffin 1,320,000 sh (unchged)
John Paulson 19,300 sh (unchged)
Jim Simons Sold Out
» More
Q4 2016

ALNY Guru Trades in Q4 2016

Dodge & Cox 9,204,950 sh (+74.47%)
Vanguard Health Care Fund 8,549,357 sh (+0.44%)
John Paulson 19,300 sh (unchged)
John Griffin 1,320,000 sh (unchged)
» More
Q1 2017

ALNY Guru Trades in Q1 2017

Jim Simons 51,100 sh (New)
Pioneer Investments 87,256 sh (New)
John Griffin 1,590,000 sh (+20.45%)
Dodge & Cox 9,399,245 sh (+2.11%)
Vanguard Health Care Fund 8,549,357 sh (unchged)
John Paulson Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ALNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:EXEL, NAS:IONS, NAS:UTHR, NAS:BIVV, NAS:GLPG, NAS:TECH, NAS:KITE, NAS:NBIX, NAS:TSRO, OTCPK:BTGGF, NAS:NKTR, NAS:BLUE, NAS:ACAD, NAS:CBPO, NAS:PBYI, NAS:ICPT, NYSE:XON, OTCPK:ABCZF, NAS:ALKS, NAS:JUNO » details
Traded in other countries:DUL.Germany,
Headquarter Location:USA
Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.

Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. Alnylam has partnered several pipeline candidates--including amyloidosis drug patisiran, hemophilia drug fitusiran, and cholesterol drug inclisiran. Up-front fees from research partnerships with firms such as Sanofi, Novartis, Medtronic, and Roche have boosted Alnylam's cash levels, and the firm stands to see milestones and royalties from drugs commercialized under these agreements.

Top Ranked Articles about Alnylam Pharmaceuticals Inc

Weekly Top Insider Buys Highlight for Week of Oct. 14 Top insider buys of the week, including Monsanto, Alnylam Pharmaceuticals, Synergy Resources and Ferrellgas Partners
Largest Insider buys for Monsanto (NYSE:MON), Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Synergy Resources Corp. (SYRG) and Ferrellgas Partners LP (NYSE:FGP). Read more...
Low Valuation Ratios Lead to Strong Portfolio Returns Backtesting Ben Graham’s Lost Formula strategy
Known as the “Father of Value Investing,” Benjamin Graham intelligently invested money in the stock market. Read more...

Ratios

vs
industry
vs
history
PB Ratio 6.82
ALNY's PB Ratio is ranked lower than
61% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. ALNY: 6.82 )
Ranked among companies with meaningful PB Ratio only.
ALNY' s PB Ratio Range Over the Past 10 Years
Min: 2.07  Med: 4.8 Max: 21.37
Current: 6.82
2.07
21.37
PS Ratio 96.20
ALNY's PS Ratio is ranked lower than
84% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. ALNY: 96.20 )
Ranked among companies with meaningful PS Ratio only.
ALNY' s PS Ratio Range Over the Past 10 Years
Min: 3.1  Med: 21.3 Max: 222.78
Current: 96.2
3.1
222.78
Current Ratio 6.23
ALNY's Current Ratio is ranked higher than
58% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. ALNY: 6.23 )
Ranked among companies with meaningful Current Ratio only.
ALNY' s Current Ratio Range Over the Past 10 Years
Min: 1.88  Med: 4.97 Max: 18.24
Current: 6.23
1.88
18.24
Quick Ratio 6.23
ALNY's Quick Ratio is ranked higher than
59% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. ALNY: 6.23 )
Ranked among companies with meaningful Quick Ratio only.
ALNY' s Quick Ratio Range Over the Past 10 Years
Min: 1.88  Med: 4.97 Max: 18.24
Current: 6.23
1.88
18.24
Days Sales Outstanding 120.83
ALNY's Days Sales Outstanding is ranked lower than
88% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. ALNY: 120.83 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALNY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.57  Med: 34.48 Max: 288.31
Current: 120.83
0.57
288.31

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.50
ALNY's 3-Year Average Share Buyback Ratio is ranked higher than
53% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. ALNY: -10.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALNY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -331.8  Med: -15.2 Max: -1
Current: -10.5
-331.8
-1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 22.08
ALNY's Price-to-Net-Cash is ranked lower than
77% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. ALNY: 22.08 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ALNY' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.7  Med: 9.38 Max: 92.77
Current: 22.08
3.7
92.77
Price-to-Net-Current-Asset-Value 19.24
ALNY's Price-to-Net-Current-Asset-Value is ranked lower than
76% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. ALNY: 19.24 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ALNY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.54  Med: 9.15 Max: 82.06
Current: 19.24
3.54
82.06
Price-to-Tangible-Book 6.82
ALNY's Price-to-Tangible-Book is ranked lower than
52% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. ALNY: 6.82 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ALNY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.2  Med: 4.9 Max: 15.16
Current: 6.82
2.2
15.16
Price-to-Median-PS-Value 4.52
ALNY's Price-to-Median-PS-Value is ranked lower than
93% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. ALNY: 4.52 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALNY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.16  Med: 1.11 Max: 8.97
Current: 4.52
0.16
8.97
Earnings Yield (Greenblatt) % -8.00
ALNY's Earnings Yield (Greenblatt) % is ranked lower than
61% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. ALNY: -8.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALNY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -18.85  Med: 465.9 Max: 1781.6
Current: -8
-18.85
1781.6

More Statistics

Revenue (TTM) (Mil) $58.77
EPS (TTM) $ -4.82
Beta3.50
Short Percentage of Float22.55%
52-Week Range $31.38 - 80.11
Shares Outstanding (Mil)86.19

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 76 145 214
EPS ($) -5.49 -5.66 -4.13
EPS without NRI ($) -5.49 -5.66 -4.13
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:ALNY

Headlines

Articles On GuruFocus.com
High Return Covered Call Trades for Alnylam Pharmaceuticals, Lumber Liquidators, Nutrisystem, 500.Co Apr 04 2017 
Weekly Top Insider Buys Highlight for Week of Oct. 14 Oct 16 2016 
Low Valuation Ratios Lead to Strong Portfolio Returns Sep 13 2016 
Liberty Broadband, Hanmi Bank Among Popular Micro-Cap Stocks Apr 04 2016 
Weekly Insider Sells Highlights: Facebook, PacWest Bancorp, Waste Management, Alnylam Pharmaceutical Nov 17 2015 
Julian Robertson Boosts His Stakes in JD.com, Netflix Oct 06 2015 
Julian Robertson Adds 16 New Stakes to Portfolio Jun 23 2015 
Gurus Purchase Tekmira Pharmaceuticals in Q1 Jun 19 2015 
Arrowhead Research Making Headway In The RNAi Therapy Platform Mar 09 2015 
Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN Feb 27 2012 

More From Other Websites
Regeneron Presents Positive Phase II Data on HoFH Candidate May 25 2017
Alnylam Pharmaceuticals (ALNY) Progressing Well on Pipeline May 25 2017
Biotech Movers: Inovio, Neurocrine, Alnylam May 24 2017
Alnylam Pharmaceuticals Prices Public Offering of Common Stock May 24 2017
Alnylam Pharmaceuticals Announces Proposed Public Offering of Common Stock May 23 2017
Alnylam Pharmaceuticals (ALNY) Looks Good: Stock Jumps 16.3% May 16 2017
How Ionis Helped Rival Alnylam — But Tanked Itself — On A Key Trial May 15 2017
Safety Concerns Ding Ionis May 15 2017
Why Ionis Pharmaceuticals Inc Tanked and Alnylam Pharmaceuticals, Inc. Is Soaring Today May 15 2017
Alnylam Pharmaceuticals, Inc. Reports Inducement Grant to New Chief Financial Officer May 12 2017
Edited Transcript of ALNY earnings conference call or presentation 5-May-17 12:30pm GMT May 12 2017
ETFs with exposure to Alnylam Pharmaceuticals, Inc. : May 11, 2017 May 11 2017
Alnylam Pharmaceuticals, Inc. Earnings: All Eyes on APOLLO May 10 2017
Alnylam to Webcast Presentations at Upcoming May Investor Conferences May 10 2017
Alnylam Pharmaceuticals, Inc. :ALNY-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 May 09 2017
Alnylam Expands Leadership Team with Multiple Experienced Biotech Leaders May 09 2017
Alnylam (ALNY) Q1 Loss Wider than Expected, Revenues Up Y/Y May 08 2017
Alnylam reports 1Q loss May 05 2017
Alnylam Pharmaceuticals Reports First Quarter 2017 Financial Results and Highlights Recent Period... May 05 2017
Investor Network: Alnylam Pharmaceuticals, Inc to Host Earnings Call May 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)